8-K: Helius Medical Technologies Announces 1-for-50 Reverse Stock Split to Maintain Nasdaq Listing

Helius Medical Technologies, Inc. has filed an 8-K announcing a 1-for-50 reverse stock split, effective June 30, 2025, to meet Nasdaq's continued listing requirements.

Summary

• Helius Medical Technologies, Inc. (HSDT) will implement a 1-for-50 reverse stock split of its Class A common stock.
• The reverse stock split was approved by stockholders on May 23, 2025, with the specific 1-for-50 ratio approved by the Board of Directors on June 20, 2025.
• The primary purpose of the reverse stock split is to enable the Company to comply with the Nasdaq Stock Market's continued listing requirements.
• The Certificate of Amendment to the Company's Certificate of Incorporation was filed with the Secretary of State of Delaware on June 27, 2025.
• The reverse stock split will become effective at 5:00 p.m. Eastern Time on June 30, 2025.
• The Company's common stock is expected to begin trading on a split-adjusted basis when the Nasdaq Stock Market opens on July 1, 2025.
• Every 50 shares of outstanding common stock will automatically be combined into 1 share.
• The number of authorized shares will remain at 150 million for Class A Common Stock and 10 million for Preferred Stock, with a par value of $0.001 per share.
• Outstanding shares will be reduced from approximately 33.8 million to approximately 0.7 million.
• Proportionate adjustments will be made to the exercise price and number of shares for outstanding stock options, restricted stock units, warrants, and equity incentive plans.
• Fractional shares will either be rounded down with cash payment based on the closing sales price on the last trading day before effectiveness, or rounded up to the next whole share, at the Company's election.
• The common stock will continue to trade on the Nasdaq Capital Market under the symbol HSDT.
• The new CUSIP number for the common stock will be 42328V 876.
• Equiniti Trust Company, LLC will serve as the exchange agent for the reverse stock split.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While the action addresses a critical compliance issue (Nasdaq listing), reverse stock splits are generally viewed unfavorably by the market as they often signal underlying financial or operational challenges leading to a depressed stock price.

Positives

• The reverse stock split is a necessary corporate action to ensure compliance with Nasdaq's continued listing requirements, preventing potential delisting.

Negatives

• Reverse stock splits are often perceived negatively by investors as they typically indicate a low stock price and underlying challenges with the company's market valuation.
• The significant reduction in outstanding shares may lead to reduced liquidity in the short term.

Risks

• Failure to maintain compliance with Nasdaq's continued listing requirements could lead to delisting, impacting the stock's liquidity and investor confidence.
• The reverse stock split may not result in a sustained increase in the stock price, and the stock could continue to trade at low valuations.

Future Outlook

The Company's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Stock Market when it opens on July 1, 2025. This action is intended to ensure continued compliance with Nasdaq's listing requirements.

Industry Context

Reverse stock splits are a common corporate action undertaken by companies, particularly those with low stock prices, to meet minimum bid price requirements of stock exchanges like Nasdaq. This move by Helius Medical Technologies aligns with similar actions taken by other companies in the medical technology or biotech sector facing similar listing challenges.

Corporate Governance

Stakeholder Impact

• Shareholders will hold fewer shares, but each share will represent a proportionately larger ownership interest and a higher per-share price, potentially meeting Nasdaq's minimum bid price requirement.
• The reverse split may impact market perception and trading liquidity for investors.

Next Steps

• The Company's Common Stock will begin trading on a split-adjusted basis on the Nasdaq Stock Market on July 1, 2025.
• Equiniti Trust Company, LLC will facilitate the exchange of shares for the reverse stock split.

Key Dates

Keywords

Helius Medical Technologies, HSDT, reverse stock split, Nasdaq listing compliance, share consolidation, corporate action, stock market, medical technology